Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 02/26/24
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/20/24
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After BunionectomyGlobeNewsWire • 02/15/24
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.GlobeNewsWire • 02/07/24
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesGlobeNewsWire • 01/04/24
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsGlobeNewsWire • 11/10/23
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberGlobeNewsWire • 11/07/23
Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23
Pacira (PCRX) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 10/26/23
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023GlobeNewsWire • 10/26/23
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.GlobeNewsWire • 10/12/23
Pacira BioSciences Appoints Four New Independent Directors to its Board of DirectorsGlobeNewsWire • 10/10/23